Bombardier Announces Pricing of its New Issuance of Senior Notes due 2032

Written by Customer Service on May 21, 2024. Posted in Public Companies.

MONTRÉAL, May 21, 2024 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has successfully priced its offering of US$750 million aggregate principal amount of new Senior Notes due June 1, 2032. The new Senior Notes will carry a coupon of 7.000% per annum and will be sold at par (the “New Notes”). The issuance of the New Notes is expected to close on or about June 5, 2024, subject to customary closing conditions. Bombardier intends to use the proceeds of the offering of the New Notes, together with cash on hand, (i) to fund the repayment and/or retirement of outstanding indebtedness, including the redemption of US$338 million aggregate principal amount of its outstanding 7.125% Senior Notes due 2026 (the “2026 Notes”, and such redemption, the “Conditional 2026 Notes Redemption”) and the redemption of US$450...

Bombardier Announces Conditional Notices of Partial Redemption for US$338,000,000 of its 7.125% Senior Notes due 2026 and US$450,000,000 of its 7.875% Senior Notes due 2027

Written by Customer Service on May 21, 2024. Posted in Public Companies.

MONTRÉAL, May 21, 2024 (GLOBE NEWSWIRE) — Bombardier Inc. (“Bombardier”) today announced that it has issued a conditional notice of partial redemption for US$338 million aggregate principal amount of its outstanding 7.125% Senior Notes due 2026 (the “2026 Notes”), and a conditional notice of partial redemption for US$450 million aggregate principal amount of its outstanding 7.875% Senior Notes due 2027 (the “2027 Notes” and, together with the 2026 Notes, the “Redemption Notes”). As set forth in the conditional notice of partial redemption issued today in respect of the 2026 Notes, the redemption date is June 20, 2024, and the redemption price for the 2026 Notes is 101.781% of the principal amount redeemed, plus accrued and unpaid interest. As set forth in the conditional notice of partial redemption issued today in respect of the...

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

Written by Customer Service on May 21, 2024. Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., May 21, 2024 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced that the Company presented clinical data and preclinical data of bexotegrast (PLN-74809) this week as part of the American Thoracic Society (ATS) 2024 International Conference, held from May 17-22, 2024. “Our 2024 ATS presentations include comprehensive clinical safety and imaging data, as well as preclinical data from our bexotegrast development program that provide further support the late-stage development of this novel therapeutic in our currently enrolling BEACON-IPF trial,” said Éric Lefebvre, M.D., Chief Medical Officer at Pliant Therapeutics. Update on the Safety...

Neon Bloom Finalizes Terms to Acquire Advanced Executive Sales, LLC

Written by Customer Service on May 21, 2024. Posted in Mergers And Acquisitions.

Acquisition and expansion into payment processing expected to close before May 31, 2024 NEWPORT BEACH, Calif., May 21, 2024 (GLOBE NEWSWIRE) — Neon Bloom, Inc. (OTC PINK: NBCO), announced today that it has finalized the terms of its acquisition of Advanced Executive Sales, LLC (AES), a leading financial services company specializing in electronic payment and card processing for all types of businesses. The two companies expect to close on the acquisition by May 31, 2024. After months of due diligence and negotiations between Neon Bloom and Mr. Greg Bauer, the Managing Member of AES, the two parties finally came to a mutual agreement as to the structure and consideration for the acquisition. As part of the final agreement, Neon Bloom will be appointing Mr. Bauer as a member of the Neon Bloom Board of Directors and an executive officer...

Helium Evolution Announces Filing of Q1-2024 Financial Results

Written by Customer Service on May 21, 2024. Posted in Earnings Releases And Operating Results.

CALGARY, Alberta, May 21, 2024 (GLOBE NEWSWIRE) — Helium Evolution Incorporated (TSXV:HEVI) (“HEVI” or the “Company“), a Canadian-based helium exploration company focused on developing assets in southern Saskatchewan, today announced the filing of the Company’s interim condensed financial statements and associated management’s discussion and analysis for the three months ended March 31, 2024 (the “Q1 Report”). Complete details of the Q1 Report are available on SEDAR+ at www.sedarplus.ca, and on HEVI’s website. Three Months Ended March 31, 2024 Highlights: Three months ended Tabular amounts in thousands ofCanadian Dollars, except share and per share amounts March 31, 2024 March 31, 2023 Financial Net loss 239 311 Net loss per share, basic and diluted 0.00 0.00 Cash 5,304 8,229 Working...

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

Written by Customer Service on May 21, 2024. Posted in Earnings Releases And Operating Results.

Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year. Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe. Alvotech raises topline revenue guidance to $400-$500 million and tightens guidance for bottom line range for 2024 to $100-$150 million. Management will conduct a business update conference call and live webcast on Wednesday May 22, 2024, at 8:00 am ET (12:00 pm GMT). REYKJAVIK, Iceland, May 21, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development...

Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

Written by Customer Service on May 21, 2024. Posted in Earnings Releases And Operating Results.

Total revenues in Q1 2024 increased to $37 million compared to $16 million in the same period last year Gross margin in Q1 2024 increased to $17 million, by $40 million compared to the same period last year. Alvotech signed new commercialization agreements for its high concentration interchangeable biosimilar to Humira® in the U.S. and for its proposed biosimilar to Prolia® and Xgeva® in the U.S. and Europe. Alvotech raises topline revenue guidance to $400-$500 million and tightens guidance for bottom line range for 2024 to $100-$150 million. Management will conduct a business update conference call and live webcast on Wednesday May 22, 2024, at 8:00 am ET (12:00 pm GMT) Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Toll Brothers Reports FY 2024 2nd Quarter Results

Written by Customer Service on May 21, 2024. Posted in Earnings Releases And Operating Results.

Bella Vista at Porter Ranch Northridge, CA FORT WASHINGTON, Pa., May 21, 2024 (GLOBE NEWSWIRE) — Toll Brothers, Inc. (NYSE:TOL) (TollBrothers.com), the nation’s leading builder of luxury homes, today announced results for its second quarter ended April 30, 2024. FY 2024’s Second Quarter Financial Highlights (Compared to FY 2023’s Second Quarter): Net income and earnings per share were $481.6 million and $4.55 per diluted share, compared to net income of $320.2 million and $2.85 per diluted share in FY 2023’s second quarter. Net income and earnings per share included $124.1 million and $1.17, respectively, related to the sale of a parcel of land to a commercial developer. Excluding these gains, net income and earnings per share were $357.5 million and $3.38 per diluted share in FY 2024’s second quarter. Pre-tax income was...

Atico Reports Consolidated Financial Results for First Quarter of 2024

Written by Customer Service on May 21, 2024. Posted in Earnings Releases And Operating Results.

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, May 21, 2024 (GLOBE NEWSWIRE) — Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the three months ended March 31, 2024, posting income from mining operations of $2.8 million and a net loss of $0.4 million. Production for the period at Atico’s El Roble mine totaled 3.3 million pounds (“lbs”) of copper and 2,185 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.57 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, “the operational and financial results for this quarter were in line with Company expectations. We are already into development of the newly discovered reserves and have been making additional investments in preparation...

Canadian Net REIT Announces 2024 First-Quarter Results

Written by Customer Service on May 21, 2024. Posted in Earnings Releases And Operating Results.

REIT also announces monthly distributions for Q3 2024 MONTRÉAL, May 21, 2024 (GLOBE NEWSWIRE) — Canadian Net Real Estate Investment Trust (“Canadian Net” or the “REIT”) (TSX-V: NET.UN) today reported its results for the quarter ended March 31st, 2024 (“Q1 2024”). The REIT also announced distributions for the months of July, August and September 2024. “I’m pleased to share our Q1 2024 results, which highlight the strength of our portfolio with a solid 100% occupancy rate and a conservative 57% payout ratio,” said Kevin Henley, President and CEO. “Our portfolio has performed very well and has mostly offset the increased interest rate cost due to higher rates on our 2023 mortgage renewals, translating into a slight 3% decrease in FFO per unit. Looking forward, our portfolio is well-positioned and will absorb these costs through...

Day: May 21, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice